Please login to the form below

Not currently logged in
Email:
Password:

Takeda ties-up with Denali Therapeutics for neuroscience boost

The companies will develop new therapies for conditions such as Alzheimer’s

TakedaTakeda Pharmaceuticals and Denali Therapeutics have entered a partnership to develop and commercialise therapies for multiple neurodegenerative diseases.

The collaboration will see the companies produce up to three specified therapeutic product candidates which will target a specific neurodegenerative disorder, including Alzheimer’s disease and other indications.

At the forefront of the work will be Denali’s ATV technology, which aims to increase exposure of biotherapeutic products for the brain.

Ryan Watts, chief executive officer of Denali, said: “We are impressed with Takeda’s commitment to developing treatments for difficult to treat neurodegenerative disease and look forward to partnering with them to bring medicines to patients.

“Takeda has a great track record of partnering with biotech firms in addition to unique development expertise and a strong global commercial presence.”

Under the terms of the agreement, Takeda will make an initial payment of $150m through a combination of cash payments and the purchase of Denali equity.

In addition, the San Francisco-based biopharma is eligible to receive development and commercial milestone payments, including $90m in preclinical milestones and opt-in payments.

Emiliangelo Ratti, head of neuroscience therapy area at Takeda, said: “We are excited to partner with the Denali team, whose innovative technology is uniquely poised to deliver the next generation of antibody therapeutics for patients.”

Despite Takeda’s recent investment in the area, its US and Irish counterparts has recently turned its back on neuroscience work with Pfizer recently exiting its early-stage R&D programmes and Shire separating out its neuroscience interests, possibly as a precursor to divestment.

Article by
Gemma Jones

10th January 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
StratX

StratX creates experiential learning programs instilled with emotion and competitive spirit, leading to lasting on-the-job change. Our memorable approach develops...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics